Skip to content
Peptigraph home

CJC-1295 + Ipamorelin and Tesamorelin Together: What Is Known

CJC-1295 + Ipamorelin and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[14]Growth hormoneGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[15]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 6 results, 2 Oct 2026).

CJC-1295 + Ipamorelin is not FDA approved, and we have no sourced data on combining it with Tesamorelin.
Each component

Side by side

Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.

FieldCJC-1295 + IpamorelinTesamorelin
ClassGHRH + GHRP blendGHRH analog
Also calledCJC/Ipatesa, Egrifta
FDA statusNot FDA approved · research blendFDA approved (Egrifta)
Anti-doping detection
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeIpamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 1049665811 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Human studies we summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients12 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold10 mg2 mg, 5 mg, 10 mg, 20 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)
Related tools

CJC-1295 + Ipamorelin vs Tesamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

A research blend against an approved drug

In rats, ipamorelin released growth hormone with potency and efficacy comparable to GHRP-6. Antagonist profiling indicated it acts through a GHRP-like receptor.[16]

Tesamorelin binds the growth-hormone-releasing-factor receptor with similar potency to the endogenous hormone, per its label's in vitro data.[9]

A review of GH-axis peptides sorts them into evidence tiers from regulatory-grade randomised trials to a complete absence of human studies, and highlights uncertainty around the putative performance and recomposition benefits.[17]

Has the blend or any of its parts met tesamorelin in a trial?

A PubMed search on 2 Oct 2026 for CJC-1295 plus ipamorelin together with tesamorelin matched 6 records; none is recorded as a trial of the combination.

Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 6; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

A randomised trial of ipamorelin for postoperative ileus after bowel resection found no significant difference from placebo in its key and secondary efficacy analyses.[5]

CJC-1295's human trials in healthy adults tracked GH, IGF-I and pharmacokinetics rather than body composition.[6]

Regulatory and sport status

FDA's note on ipamorelin cites a study where serious adverse events including death occurred when it was given intravenously for gut motility.[18]

For CJC-1295, FDA's note names a raised heart rate and a systemic vasodilatory reaction among serious adverse events.[18]

Egrifta WR's label lists active malignancy as a contraindication.[9]

WADA lists the GHRH class that names CJC-1295 and tesamorelin, and separately names ipamorelin among secretagogues.[2]

Common questions

CJC-1295 ipamorelin vs tesamorelin: which is better?

The cached sources include a randomised outcome trial and an FDA label for tesamorelin. None tests the CJC-1295 and ipamorelin blend itself.[15]

Can you stack tesamorelin with CJC-1295 and ipamorelin?

No study in the cached results tested the three together. Tesamorelin's label says the effects of prolonged IGF-1 elevation are unknown.[9]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  4. 4Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  5. 5Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  6. 6Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  7. 7An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  8. 8Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  9. 9EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  11. 11Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  12. 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  13. 13PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  15. 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  16. 16Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
  17. 17The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  18. 18Official web pageOfficial web page · web page

Found an error? Report a correction.